Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949884 · ClinicalTrials.gov registry record · Phase 4
Olmesartan Comparison to Losartan in Hypertensive Subjects
A Phase 4 study of Hypertension, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 941
- Enrollment target
- 20
- Study locations
NCT00949884: Completed Phase 4 study of Hypertension, sponsored by Daiichi Sankyo.
NCT00949884 is a Phase 4 study of Hypertension that has completed, run by Daiichi Sankyo. The registered enrollment target is 941 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00949884, a Phase 4 study of Hypertension, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 941 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of the FDA approved blood pressure medication olmesartan medoxomil compared to the FDA approved medication losartan potassium.
Primary Outcome
The change from baseline in trough SDBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 sea
Conditions Studied
Interventions
- DRUG Placebo
- DRUG olmesartan medoxomil
- DRUG losartan potassium
Study Locations (20)
California
- - Harbor City
- - Tustin
- - Westlake Village
Arizona
- - Mesa
- - Phoenix
Florida
- - Deerfield Beach
- - DeLand
Tennessee
- - Bristol
- - New Tazewell
Colorado
- - Pueblo
Indiana
- - South Bend
Kansas
- - Wichita
Louisiana
- - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
What the finished NCT00949884 record still lists
NCT00949884 is an interventional study that assigns participants to a tested intervention. The registered 941 participants enrollment target is mid-sized for trials with a published cap, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00949884 names 20 study sites across 15 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00949884 about?
NCT00949884 is a clinical study titled "Olmesartan Comparison to Losartan in Hypertensive Subjects". This study will evaluate the efficacy and safety of the FDA approved blood pressure medication olmesartan medoxomil compared to the FDA approved medication losartan potassium.
What is the current status of trial NCT00949884?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 941 participants. The study started on 2009-08. Estimated completion is 2010-01.
What conditions does trial NCT00949884 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00949884?
The interventions under investigation include: Placebo (DRUG), olmesartan medoxomil (DRUG), losartan potassium (DRUG).
Who is sponsoring clinical trial NCT00949884?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00949884 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00949884's enrollment target sits among peer trials
941 79th of 470 higher than 392 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia